300 related articles for article (PubMed ID: 8684154)
1. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials.
Parsonnet J; Harris RA; Hack HM; Owens DK
Lancet; 1996 Jul; 348(9021):150-4. PubMed ID: 8684154
[TBL] [Abstract][Full Text] [Related]
2. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer.
Fendrick AM; Chernew ME; Hirth RA; Bloom BS; Bandekar RR; Scheiman JM
Arch Intern Med; 1999 Jan; 159(2):142-8. PubMed ID: 9927096
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of screen-and-treat strategy in asymptomatic Chinese for preventing Helicobacter pylori-associated diseases.
Chen Q; Liang X; Long X; Yu L; Liu W; Lu H
Helicobacter; 2019 Apr; 24(2):e12563. PubMed ID: 30672082
[TBL] [Abstract][Full Text] [Related]
4. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis.
Yeh JM; Hur C; Ward Z; Schrag D; Goldie SJ
Gut; 2016 Apr; 65(4):563-74. PubMed ID: 25779597
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation.
Roderick P; Davies R; Raftery J; Crabbe D; Pearce R; Patel P; Bhandari P
J Med Screen; 2003; 10(3):148-56. PubMed ID: 14561268
[TBL] [Abstract][Full Text] [Related]
6. Family-based Helicobacter pylori infection control and management strategy and screen-and-treat strategy are highly cost-effective in preventing multiple upper gastrointestinal diseases in Chinese population at national level.
Zhang C; Qi YB; Hu RB; Xu L; Li XT; Ma J; Shao QQ; Abdun MA; Ur Rahman I; Shi WJ; Li FQ; Yu JJ; Yuan MK; Chen Q; Lu H; Ding SZ
Helicobacter; 2024; 29(3):e13063. PubMed ID: 38874128
[TBL] [Abstract][Full Text] [Related]
7. Both family-based Helicobacter pylori infection control and management strategy and screen-and-treat strategy are cost-effective for gastric cancer prevention.
Ma J; Yu M; Shao QQ; Yu XC; Zhang C; Zhao JB; Yuan L; Qi YB; Hu RB; Wei PR; Xiao W; Chen Q; Jia BL; Chen CL; Lu H; Ding SZ
Helicobacter; 2022 Aug; 27(4):e12911. PubMed ID: 35706404
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention.
Lansdorp-Vogelaar I; Sharp L
Best Pract Res Clin Gastroenterol; 2013 Dec; 27(6):933-47. PubMed ID: 24182612
[TBL] [Abstract][Full Text] [Related]
9. A screening program to test and treat for Helicobacter pylori infection: Cost-utility analysis by age, sex and ethnicity.
Teng AM; Kvizhinadze G; Nair N; McLeod M; Wilson N; Blakely T
BMC Infect Dis; 2017 Feb; 17(1):156. PubMed ID: 28219322
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of
Kowada A
Scand J Gastroenterol; 2019 Jun; 54(6):685-689. PubMed ID: 31190581
[No Abstract] [Full Text] [Related]
11. Cost effectiveness analysis of population-based serology screening and (13)C-Urea breath test for Helicobacter pylori to prevent gastric cancer: a markov model.
Xie F; Luo N; Lee HP
World J Gastroenterol; 2008 May; 14(19):3021-7. PubMed ID: 18494053
[TBL] [Abstract][Full Text] [Related]
12. [Cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: Markov decision analysis].
Wang Q; Jin PH; Lin GW; Xu SR; Chen J
Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Feb; 24(2):135-9. PubMed ID: 12697117
[TBL] [Abstract][Full Text] [Related]
13. Economic and health impacts of introducing Helicobacter pylori eradication strategy into national gastric cancer policy in Japan: A cost-effectiveness analysis.
Kowada A; Asaka M
Helicobacter; 2021 Oct; 26(5):e12837. PubMed ID: 34278663
[TBL] [Abstract][Full Text] [Related]
14. Helicobacter pylori test-and-treat program can be cost-effective to prevent gastric cancer in Taiwanese adults: referred to the nationwide reimbursement database.
Cheng HC; Wang JD; Chen WY; Chen CW; Chang SC; Sheu BS
Helicobacter; 2015 Apr; 20(2):114-24. PubMed ID: 25382169
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of Helicobacter pylori Eradication Therapy for Prevention of Gastric Cancer: A Markov Model.
Han Y; Yan T; Ma H; Yao X; Lu C; Li Y; Li L
Dig Dis Sci; 2020 Jun; 65(6):1679-1688. PubMed ID: 31673902
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer.
Lee YC; Lin JT; Wu HM; Liu TY; Yen MF; Chiu HM; Wang HP; Wu MS; Hsiu-Hsi Chen T
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):875-85. PubMed ID: 17507609
[TBL] [Abstract][Full Text] [Related]
17. Helicobacter Pylori and Gastric Cancer: Clinical Aspects.
Song ZQ; Zhou LY
Chin Med J (Engl); 2015 Nov; 128(22):3101-5. PubMed ID: 26608993
[TBL] [Abstract][Full Text] [Related]
18. Helicobacter pylori and gastric cancer: what are the benefits of screening only for the CagA phenotype of H. pylori?
Harris RA; Owens DK; Witherell H; Parsonnet J
Helicobacter; 1999 Jun; 4(2):69-76. PubMed ID: 10382118
[TBL] [Abstract][Full Text] [Related]
19. Is there a rationale for eradication of Helicobacter pylori? Cost-benefit: the case for.
Moayyedi P; Axon AT
Br Med Bull; 1998; 54(1):243-50. PubMed ID: 9604447
[TBL] [Abstract][Full Text] [Related]
20. A Population-Based Helicobacter pylori Eradication Strategy Is More Cost-Effective than Endoscopic Screening.
Kowada A
Dig Dis Sci; 2023 May; 68(5):1735-1746. PubMed ID: 36565366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]